Hunter Syndrome and Bull's Eye Maculopathy.

Competing Interests: D. B. is a consultant and speaker for Novartis and Bayer, and a consultant for Alcon. D. R. M. is a consultant for Bayer and Roche. B. L. is outside of the submitted work member of the steering committee of HOS, a post-marketing registry for Hunterʼs disease and received honoraria and travel grants by Shire, Takeda, Genzyme-Sanofi, and Alexion for various presentations. None of the declarations represent a conflict of interest related to the presented study. S. S., J. M. G., J. V. M. H., K. F., F. B., and S. A. Z. declare no conflict of interest related to the topic.